Company Overview
ProMIS Neurosciences, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry by discovering and developing antibody therapies and therapeutic vaccines designed to treat neurodegenerative diseases and other misfolded protein diseases in Canada. The company leverages a proprietary discovery platform that utilizes ProMIS and Collective Coordinates algorithms to predict novel targets, aiming to advance treatments for complex neurological conditions. In terms of scale, the entity holds a market capitalization of $142.14M, operates with an annual revenue figure that is not currently disclosed as a specific number in available records, and employs a workforce count that is listed as N/A. These valuation metrics indicate that the company is a mid-sized biotechnology entity with a market cap that reflects the high-risk, high-potential nature typical of firms in the early stages of therapeutic development, where revenue generation is often secondary to research and development milestones.
Financial Health
The financial profile of ProMIS Neurosciences, Inc. reveals a net income of $-39,719,148 for the trailing twelve months, while both revenue and EBITDA figures are listed as N/A or 0.0% in the available data, highlighting a significant gap between potential revenue streams and actual profitability. The absence of reported free cash flow suggests that the company is currently consuming cash to fund its operations and development pipeline rather than generating surplus liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet achieved positive profitability on its sales or operations. Regarding balance sheet composition, the company holds $6.15M in cash against a debt level that is not disclosed, resulting in a debt-to-equity ratio that is listed as N/A. The current ratio stands at 0.88, indicating that the company's current assets are slightly below its current liabilities, which suggests a potential liquidity constraint typical for pre-revenue biotech firms. Return on Equity is reported at -521.6% and Return on Assets at -178.7%, metrics that reveal management is currently utilizing shareholder capital and assets to generate negative returns, a common characteristic of companies investing heavily in R&D before reaching commercialization.
Valuation Assessment
Valuation multiples for ProMIS Neurosciences, Inc. show a P/E Ratio (TTM) that is N/A and a Forward P/E of -25.98, implying that the market is pricing in future earnings recovery after a period of significant losses. The price-to-book ratio is reported as -27.09, a negative figure that indicates the company's market value is significantly below its book value, often seen in firms with intangible asset-heavy balance sheets or those not yet profitable. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are listed as N/A, suggesting that traditional valuation models relying on sales or earnings are not applicable at this stage of the company's lifecycle. The stock has traded between a 52-week high of $39.75 and a 52-week low of $6.27, meaning the current price sits within a wide volatility range that reflects the speculative nature of the biotechnology sector. The beta value is listed as N/A, preventing a direct comparison of the stock's price volatility relative to the broader market, though the wide spread between the high and low suggests high sensitivity to market sentiment and clinical trial news.
Growth & Income
Growth metrics for ProMIS Neurosciences, Inc. show revenue growth year-over-year and earnings growth year-over-year both listed as N/A, indicating that the company is not yet in a stage of consistent commercial expansion. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which means the company reinvests all available earnings, or rather its limited cash resources, back into research and development rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology firms that must prioritize funding clinical trials and drug development over providing immediate returns to investors. The overall growth and income profile is characterized by a lack of current financial returns and no dividend distribution, focusing entirely on the long-term potential of its antibody therapies and vaccines for neurodegenerative diseases.